Marcela V. Maus, M.d.,ph.d.

This study tested whether adding anakinra to standard CAR-T cell therapy could prevent serious brain and nerve side effects in people with relapsed or treatment-resistant non-Hodgkin lymphoma. Fifteen participants received the combination. The goal was to lower the risk of neurot…